An observational study suggests not.
Recommended medications for migraine treatment include triptans, nonsteroidal anti-inflammatory agents, prochlorperazine or metoclopramide, and caffeine. All can be given orally, subcutaneously, or intramuscularly. No evidence supports the placement of intravenous (IV) catheters in migraine patients.
In a post-hoc observational study of data from four emergency department-based randomized trials of IV metoclopramide, investigators compared outcomes between 120 participants who received IV fluids at the treating physician's discretion and 458 who did not. At 1 hour, patients who received IV fluids had less improvement in pain than those who did not receive IV fluids (improvement of 4.5 vs. 5.1 points on a 0-to-10-point scale).
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals